Previous data suggested interaction of @entity900 with interferon (IFN) in @entity1149 and a possible effect of IFN in maintaining remission in @entity151 ( @entity151 ). This study was designed to further examine the effect of IFN in the treatment of @entity66 ( @entity66 ) @entity151 . Forty previously untreated @entity1 with performance status (PS) of 0-2 (Zubrod scale) were treated with @entity2879 (100 mg/m2 for 3 days), @entity900 (25 mg/m2 for 3 days) (EP), and recombinant IFN-alpha2a (rIFN-alpha2a) (5 x 10(6) U/m2 for 3 days) for six cycles (induction), followed by rIFN-alpha2a (5 x 10(6) U/m2) thrice weekly and @entity6303 (40 mg q.i.d.) as maintenance therapy for 6 months or until progressive disease or intolerable @entity137 was documented. @entity1 were 25 @entity1 (62%) and 15 @entity1 (38%), median age 58 (28-76), median Zubrod performance status 1 (0-2). Major sites of metastasis include liver (55%), bone (42%), bone marrow (25%), and adrenal gland (18%). Of 40 eligible @entity1 accrued to this trial, 35 were evaluable for response, and 37 were evaluable for @entity137 . There were 3 complete and 28 partial responses, for an overall response rate of 89%. With 39 of 40 @entity1 followed until @entity204 , median survival (Kaplan-Meier) is estimated at 46 weeks (95% CI range 35-55). Twenty @entity1 completed six cycles of induction, and 16 received maintenance therapy, median 2 cycles (range 1-3). Major @entity137 during induction included grade 4 @entity3028 in 24%, grade 2-3 @entity390 or @entity391 or both in 41%, grade 2 @entity1295 in 24%, grade 2 @entity448 in 22%, and grade 2-3 @entity177 in 9% of 175 total courses of chemotherapy administered. @entity137 during the maintenance phase was notable for grade 2-3 @entity1295 in 43%, grade 2-3 @entity448 in 24%, grade 2-3 weight loss in 10%, and grade 3-4 @entity417 in 17% of 30 courses. There were no treatment-related @entity204 . The addition of rIFN-alpha2a to EP in induction chemotherapy of @entity66 @entity151 , followed by rIFN-alpha2a and @entity6303 maintenance therapy, was reasonably well tolerated. The complete and overall response rates and duration of remission and survival appear to be similar to those generally obtained with EP alone in similar @entity1 .

Phase II trial of recombinant IFN-alpha2a with @entity2879 / @entity900 induction and interferon/ XXXX maintenance in extensive @entity151 .

@entity1 :: ('9606', 'Species') :: ['men', 'women', 'Patients', 'patients'] @entity137 :: ('MESH:D064420', 'Disease') :: ['Toxicity', 'toxicity'] @entity390 :: ('MESH:D009325', 'Disease') :: ['nausea'] @entity66 :: ('MESH:D004194', 'Disease') :: ['ED', 'extensive disease'] @entity417 :: ('MESH:D000740', 'Disease') :: ['anemia'] @entity1149 :: ('MESH:D002289', 'Disease') :: ['non-small cell lung cancer'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity391 :: ('MESH:D014839', 'Disease') :: ['vomiting'] @entity3028 :: ('MESH:D000380', 'Disease') :: ['granulocytopenia'] @entity2879 :: ('MESH:D005047', 'Chemical') :: ['etoposide'] @entity1295 :: ('MESH:D005221', 'Disease') :: ['fatigue'] @entity448 :: ('MESH:D000855', 'Disease') :: ['anorexia'] @entity177 :: ('MESH:D051437', 'Disease') :: ['renal insufficiency'] @entity6303 :: ('MESH:D019290', 'Chemical') :: ['megestrol acetate'] @entity151 :: ('MESH:D055752', 'Disease') :: ['SCLC', 'small cell lung cancer'] @entity204 :: ('MESH:D003643', 'Disease') :: ['death', 'deaths']
@entity6303 :: (MESH:D019290,Chemical) :: ['megestrol acetate']
